Replimune Group (REPL) Competitors $4.73 +0.08 (+1.72%) Closing price 04:00 PM EasternExtended Trading$4.65 -0.08 (-1.69%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. SION, TLRY, PHVS, AMPH, ZYME, EVO, ATAI, TRML, CVAC, and LENZShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Sionna Therapeutics (SION), Tilray Brands (TLRY), Pharvaris (PHVS), Amphastar Pharmaceuticals (AMPH), Zymeworks (ZYME), Evotec (EVO), atai Life Sciences (ATAI), Tourmaline Bio (TRML), CureVac (CVAC), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Sionna Therapeutics Tilray Brands Pharvaris Amphastar Pharmaceuticals Zymeworks Evotec atai Life Sciences Tourmaline Bio CureVac LENZ Therapeutics Replimune Group (NASDAQ:REPL) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Do insiders and institutionals hold more shares of REPL or SION? 92.5% of Replimune Group shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, REPL or SION? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.46Sionna TherapeuticsN/AN/A-$61.69MN/AN/A Is REPL or SION more profitable? Sionna Therapeutics' return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Sionna Therapeutics N/A N/A N/A Do analysts recommend REPL or SION? Replimune Group presently has a consensus target price of $6.50, suggesting a potential upside of 37.42%. Sionna Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 26.62%. Given Replimune Group's higher probable upside, research analysts clearly believe Replimune Group is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 3 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.91Sionna Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media favor REPL or SION? In the previous week, Sionna Therapeutics had 17 more articles in the media than Replimune Group. MarketBeat recorded 18 mentions for Sionna Therapeutics and 1 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.34 beat Sionna Therapeutics' score of 0.33 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySionna Therapeutics beats Replimune Group on 7 of the 11 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$362.96M$3.32B$6.06B$10.59BDividend YieldN/A2.28%5.52%4.66%P/E Ratio-1.468.0358.3422.96Price / SalesN/A457.06602.84131.54Price / CashN/A46.6137.7361.25Price / Book0.889.9312.556.55Net Income-$247.30M-$52.59M$3.30B$277.26M7 Day Performance14.53%5.28%28,056.17%2.41%1 Month Performance-19.69%12.54%28,977.34%9.26%1 Year Performance-59.54%28.76%35,796.37%32.66% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.7443 of 5 stars$4.73+1.7%$6.50+37.4%-62.1%$362.96MN/A-1.46210Positive NewsSIONSionna Therapeutics2.9439 of 5 stars$29.52+2.0%$38.00+28.7%N/A$1.28BN/A0.0035Insider TradeTLRYTilray Brands2.703 of 5 stars$1.85+60.9%$1.94+4.7%-4.2%$1.27B$821.31M0.002,842Upcoming EarningsGap UpHigh Trading VolumePHVSPharvaris2.3099 of 5 stars$24.26+0.4%$34.00+40.1%+26.5%$1.26BN/A0.0030Positive NewsAMPHAmphastar Pharmaceuticals4.448 of 5 stars$26.92+0.3%$31.60+17.4%-43.0%$1.25B$731.97M8.772,028Positive NewsZYMEZymeworks0.015 of 5 stars$17.23+3.8%N/AN/A$1.25B$76.30M-17.76460EVOEvotec1.6089 of 5 stars$3.54+1.7%$5.40+52.5%+13.5%$1.24B$862.40M0.004,827ATAIatai Life Sciences3.3784 of 5 stars$5.45+3.4%$11.25+106.4%+371.6%$1.23B$310K-7.9080News CoverageTRMLTourmaline Bio1.5589 of 5 stars$48.16+0.9%$45.65-5.2%+80.6%$1.23BN/A0.0044Short Interest ↓CVACCureVac4.0306 of 5 stars$5.35-0.4%$6.83+27.7%+79.7%$1.20B$579.18M5.59880News CoverageLENZLENZ Therapeutics0.7126 of 5 stars$44.89+6.8%$49.60+10.5%+111.1%$1.20BN/A0.00110 Related Companies and Tools Related Companies Sionna Therapeutics Alternatives Tilray Brands Alternatives Pharvaris Alternatives Amphastar Pharmaceuticals Alternatives Zymeworks Alternatives Evotec Alternatives atai Life Sciences Alternatives Tourmaline Bio Alternatives CureVac Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
